▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #149 by analyst upside · 2026-09-14
GNLX
Genelux Corporation
Healthcare · Market Cap $113M · P/E 0x
ANALYST PRICE TARGET
+663.1%
implied upside to consensus target
Current Price $2.49
Consensus Target $19.0
Bull Target $31.0
Bear Target $12.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $2.29
52-Week High $8.54
YTD Return -45.3%
FUNDAMENTALS
Market Cap $113M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.86
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.29
52-Week High $8.54
Current Price $2.49
Bear Target $12.0
Bull Target $31.0
● Now $2.49 ● Target $19.0
TRADING DATA
Avg Volume 267K
YTD Return -45.3%
Analyst Count 5
Consensus Buy
Upside to Target +663.1%
Last Updated 2026-09-14

ANALYST SUMMARY

Genelux Corporation (GNLX) is currently trading at $2.49 with a Wall Street consensus price target of $19.0, implying potential upside of 663.1% over the next 12 months. 5 analysts currently cover GNLX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $31.0, while the most cautious has a target of $12.0.

GNLX operates in the Healthcare sector with a market capitalisation of $113M. The stock is down 45.3% year-to-date and is currently trading near the lower end of its 52-week range of $2.29 – $8.54.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

DWTX +621.6%
Dogwood Therapeutics, Inc.
$66M · P/E 1.0x · Strong Buy
VXRT +580.3%
Vaxart, Inc.
$119M · P/E 2.9x · Buy
GTBP +771.1%
GT Biopharma, Inc.
$16M · P/E 0.1x · Buy
PALI +396.2%
Palisade Bio, Inc.
$359M · P/E 3.2x · Buy
FBIO +336.5%
Fortress Biotech, Inc.
$84M · P/E 0.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GNLX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Benchmark - Reiterated
Speculative Buy → Speculative Buy 2026-03-20 Building track record
Lake Street ● Initiated
Buy 2025-10-21 27% win rate (11 calls)
LUCID CAPITAL MARKETS ● Initiated
Buy 2025-07-21 40% win rate (5 calls)
Benchmark - Reiterated
Speculative Buy → Speculative Buy 2025-05-08 Building track record
HC Wainwright & Co. reit
Buy → Buy 2025-03-31 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-25 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2024-11-15 31% win rate (48 calls)
Guggenheim ● Initiated
Buy 2024-10-29 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →